Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CRVS

Corvus Pharmaceuticals Inc

May 09 • 09:30AM ET

2.06

Dollar change +0.10
Percentage change 5.34	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.51	Insider Own	24.75%	Shs Outstand	49.04M	Perf Week	19.34%
Market Cap	101.25M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	5.18%	Shs Float	36.90M	Perf Month	36.73%
Income	-24.86M	PEG	-	EPS next Q	-0.11	Inst Own	17.98%	Short Float	3.70%	Perf Quarter	3.23%
Sales	0.00M	P/S	-	EPS this Y	14.17%	Inst Trans	-13.31%	Short Ratio	5.53	Perf Half Y	30.67%
Book/sh	0.68	P/B	3.03	EPS next Y	-13.36%	ROA	-50.58%	Short Interest	1.37M	Perf Year	59.43%
Cash/sh	0.45	P/C	4.58	EPS next 5Y	-	ROE	-60.46%	52W Range	1.05 - 4.19	Perf YTD	17.31%
Dividend Est.	-	P/FCF	-	EPS past 5Y	19.89%	ROI	-74.50%	52W High	-50.73%	Beta	1.05
Dividend TTM	-	Quick Ratio	3.40	Sales past 5Y	0.00%	Gross Margin	-	52W Low	96.63%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	3.40	EPS Y/Y TTM	41.77%	Oper. Margin	0.00%	RSI (14)	64.87	Volatility	16.79% 11.02%
Employees	28	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.50	Target Price	7.83
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	31.22%	Payout	-	Rel Volume	1.93	Prev Close	1.96
Sales Surprise	-	EPS Surprise	11.11%	Sales Q/Q	-	Earnings	May 06 AMC	Avg Volume	247.02K	Price	2.06
SMA20	30.88%	SMA50	15.87%	SMA200	15.10%	Trades		Volume	23,811	Change	5.34%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-18-23	Initiated	Oppenheimer	Outperform	$7
Dec-01-21	Resumed	Jefferies	Buy	$8
May-27-21	Initiated	Cantor Fitzgerald	Overweight	$10
Feb-10-21	Downgrade	Mizuho	Buy → Neutral	$7 → $4
Sep-12-19	Initiated	Mizuho	Buy
May-29-19	Initiated	ROTH Capital	Buy	$6
Aug-24-17	Upgrade	Credit Suisse	Underperform → Neutral
May-01-17	Downgrade	Credit Suisse	Neutral → Underperform
Apr-18-16	Initiated	Guggenheim	Buy
Apr-18-16	Initiated	Credit Suisse	Outperform

May-07-24 05:12PM	Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing (MT Newswires) -12.04%
11:07AM	Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:35AM	Q1 2024 Corvus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Corvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-06-24 08:58PM	CRVS Stock Earnings: Corvus Pharma Misses EPS for Q1 2024 (InvestorPlace)
04:21PM	Loading…
04:21PM	Corvus: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 04:02PM	Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 (GlobeNewswire) +7.45%
08:30AM	Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering (GlobeNewswire)
Apr-17-24 09:35AM	Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks (Zacks) -7.48%
Apr-09-24 04:01PM	Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
Apr-01-24 09:35AM	Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround (Zacks)
Mar-22-24 12:00PM	Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-21-24 09:48AM	Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-20-24 06:32AM	Q4 2023 Corvus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.61%
04:08PM	Loading…
Mar-19-24 04:08PM	Corvus: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-13-24 04:02PM	Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024 (GlobeNewswire)
Feb-12-24 09:22AM	Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up (Zacks)
08:30AM	Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases (GlobeNewswire)
Feb-08-24 04:05PM	Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma (GlobeNewswire)
Feb-06-24 04:05PM	Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer (GlobeNewswire)
Jan-23-24 05:00PM	Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell (GlobeNewswire)
Dec-11-23 12:00PM	What Makes Corvus (CRVS) a New Buy Stock (Zacks) -16.15%
Dec-09-23 12:00PM	Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial (GlobeNewswire)
Dec-07-23 09:40AM	Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year? (Zacks)
Nov-21-23 09:40AM	Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year? (Zacks) -6.67%
Nov-08-23 11:56AM	Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:43AM	Q3 2023 Corvus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 04:32PM	Corvus: Q3 Earnings Snapshot (Associated Press Finance) +6.76%
04:01PM	Loading…
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 09:15AM	Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition (GlobeNewswire)
Nov-01-23 07:31PM	Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases (GlobeNewswire)
Oct-31-23 04:02PM	Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023 (GlobeNewswire)
Sep-06-23 04:05PM	Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA (GlobeNewswire)
Aug-30-23 10:01AM	2 Strong Buy Stocks Under $10 That Oppenheimer Sees Surging Over 200% Heres Why They Could Jump (TipRanks) +12.14%
Aug-08-23 04:35PM	Corvus: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-01-23 08:30AM	Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023 (GlobeNewswire)
Jul-06-23 12:59PM	Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818) (GlobeNewswire)
Jun-29-23 07:00AM	Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference (GlobeNewswire) -5.11%
Jun-15-23 07:00AM	Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma (GlobeNewswire) -25.67%
Jun-04-23 08:10AM	Individual investors among Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) largest shareholders, saw gain in holdings value after stock jumped 23% last week (Simply Wall St.)
May-31-23 08:30AM	Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
08:11AM	3 High-Potential Penny Stocks to Buy Now (InvestorPlace)
May-26-23 09:40AM	Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? (Zacks) -7.14%
May-17-23 09:00AM	Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma (GlobeNewswire) +36.71%
May-12-23 10:04AM	Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why (Zacks)
May-10-23 04:06PM	Why Are Corvus Pharmaceuticals Trading Higher Today (Benzinga) +32.05%
May-08-23 04:11PM	Corvus: Q1 Earnings Snapshot (AP Finance) +8.33%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-24-23 08:38AM	Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) -5.66%
Apr-20-23 09:00AM	Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023 (GlobeNewswire)
Apr-17-23 09:00AM	Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +6.73%
Apr-03-23 08:30AM	CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma (GlobeNewswire) +9.35%
Mar-30-23 06:08AM	Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2022 Earnings Call Transcript (Insider Monkey) +10.02%
Mar-28-23 04:02PM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-21-23 04:05PM	Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023 (GlobeNewswire)
Mar-14-23 04:35PM	Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-21-23 02:34PM	Corvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-Emergence (Benzinga)
09:51AM	'Block-and-lock' HIV path targeted by UCSF professor, Peninsula drug company (American City Business Journals)
07:00AM	Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818s (ITK Inhibitor) Potential to Block HIV Latency Reversal (GlobeNewswire)
Feb-02-23 05:41AM	Quite a few insiders invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) last year which is positive news for shareholders (Simply Wall St.)
Dec-12-22 10:00AM	Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition (GlobeNewswire)
Dec-05-22 08:30AM	Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022 (GlobeNewswire)
Nov-14-22 08:30AM	James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology (GlobeNewswire)
Nov-03-22 04:05PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
09:52AM	Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition (GlobeNewswire)
Oct-27-22 04:05PM	Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022 (GlobeNewswire)
Oct-25-22 04:05PM	Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer (GlobeNewswire)
Oct-14-22 09:55AM	Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-04-22 01:15PM	10 Best Stocks to Buy Now According to Jeffrey Diehls Adams Street Partners (Insider Monkey)
Sep-27-22 08:51AM	Corvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck Cancer (Benzinga)
Sep-26-22 04:05PM	Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China (GlobeNewswire)
Sep-06-22 04:05PM	Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-26-22 06:13AM	Great news for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS): Insiders acquired stock in large numbers last year (Simply Wall St.)
Aug-11-22 12:00PM	Corvus (CRVS) Moves to Buy: Rationale Behind the Upgrade (Zacks) +12.01%
Aug-08-22 04:05PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-28-22 04:05PM	Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 8, 2022 (GlobeNewswire)
Jul-21-22 04:05PM	Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research (GlobeNewswire) +7.41%
May-10-22 07:30AM	Corvus Pharmaceuticals Provides Program Updates at R&D Symposium (GlobeNewswire) +8.93%
May-07-22 09:43AM	We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely (Simply Wall St.)
May-05-22 04:05PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
Apr-26-22 07:30AM	Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York (GlobeNewswire)
Mar-19-22 08:06AM	Leiv Lea Is The Chief Financial Officer of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) And They Just Picked Up 25% More Shares (Simply Wall St.)
Mar-10-22 04:05PM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-03-22 04:30PM	Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022 (GlobeNewswire)
Jan-13-22 06:30PM	Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China (GlobeNewswire)
Jan-01-22 07:43AM	Insiders who bought stock earlier this year lose -US$118k as Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) drops to US$112m (Simply Wall St.)
Dec-13-21 09:00AM	New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation (GlobeNewswire)
Nov-12-21 07:00AM	Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-10-21 04:05PM	Corvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-02-21 04:05PM	Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
09:00AM	We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Nov-01-21 04:05PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results (GlobeNewswire) +6.62%
Oct-27-21 04:05PM	Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China (GlobeNewswire)
Oct-25-21 07:30PM	Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818 (PR Newswire)
Sep-29-21 07:11AM	The Zacks Analyst Blog Highlights: Condor Hospitality Trust, Corvus Pharmaceuticals, Covenant Logistics and Herc Holdings (Zacks) -8.27%
Sep-28-21 02:30PM	4 Buy-Ranked Stocks that Soared Over 20% in the Past Week (Zacks) -10.17%
Sep-27-21 10:08AM	3 Biotech Stocks That Could Make You Filthy Rich (Motley Fool) +12.79%

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MILLER RICHARD A MD	President and CEO	May 06 '24	Buy	1.73	577,634	1,000,000	577,634	May 07 05:05 PM
Jones William Benton	See Remarks	May 06 '24	Buy	1.73	20,000	34,624	153,773	May 07 05:06 PM
Grais Linda	Director	May 15 '23	Buy	2.45	10,000	24,500	10,000	May 16 04:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRVS

Corvus Pharmaceuticals Inc

Upgrade your FINVIZ experience